泰格醫藥(300347.SZ)擬參投蘇州泰福懷謹創業投資合夥企業(有限合夥) 主投生物醫藥、生物技術、醫療健康及相關領域的企業
格隆匯 10 月 20日丨泰格醫藥(300347.SZ)公佈,公司投資平台杭州泰格股權投資合夥企業(有限合夥)擬以自有資金投資蘇州泰福懷謹創業投資合夥企業(有限合夥)(暫定名,以後續工商登記為準,“合夥企業”)。合夥企業認繳出資總額預計為人民幣8.32億元,公司將作為該合夥企業的有限合夥人(LP)認繳出資額為人民幣6億元。合夥企業主要投資於生物醫藥、生物技術、醫療健康及相關領域的企業。
公司此次投資合夥企業,可以結合公司在醫藥臨牀研究領域的專業優勢,拓展公司投資渠道,獲取投資收益。同時該合作模式也將幫助公司提升綜合服務能力,發展優質項目儲備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.